phenotype, which presents in most cases as a progressive amnestic dementia related to other Alzheimer's-related changes that involve the medial temporal structures early in the course of disease. Furthermore, the episodic memory disorders of AD correlate well with a distribution of neurofibrillary tangles within the medial temporal lobe (MTL) and with the demonstration by MRI of volumetric loss of the hippocampus, the structure known to be critical for episodic memory.
In addition, recently developed disease-modifying therapies require early intervention at the prodromal stage before full-blown dementia.
At the moment, the prodromal stage of AD is included under the heterogeneous term mild cognitive impairment (MCI). This heterogeneity may have contributed to the negative outcomes of clinical trials in which none of the drugs was successful in delaying the time to diagnosis of AD. It may be assumed that the heterogeneity of MCI has diluted the potential for a significant treatment effect, particularly considering that AD is already at work on the brain long before the onset of clinical dementia. However, it is possible to recognise this pre-dementia stage of AD by adopting a multidimensional approach, identifying:
• a specific amnestic disorder of the hippocampal type;
• the atrophy of medial temporal structures -specifically the hippocampus; and
• the specific profile of cerebrospinal fluid biomarkers or of metabolic neuroimaging changes.
An international working group was convened to discuss the opportunity to develop a diagnostic framework for AD that would include the prodromal stages. At the end of this consensus meeting it was concluded that it was possible to recognise AD at the prodromal, pre-dementia stage with the use of specific memory tests, biomarkers and neuroimaging investigations. There was no longer a reason to limit the diagnosis of AD to patients who reached the threshold of fullblown dementia. Accordingly, it was decided that new criteria be proposed that would apply both in the early stages and across the full spectrum of the illness.
Proposed Diagnostic Criteria for Probable

Alzheimer's Disease
The framework addresses the presentations that are typical of AD. It excludes atypical presentations -primary progressive aphasia and visuospatial dysfunction -although it has been demonstrated that these atypical phenotypes can be associated with post mortem AD histological changes. To meet criteria for probable AD, an affected individual must fulfil the core clinical criterion (criterion A) and at least one of the supportive biomarker criteria (see Table 1 Alzheimer's disease… DOI:10.17925/ENR.2007.00.02.53 To satisfy criterion A, memory symptoms must start gradually and show progressive decline over at least six months. Particular attention should be paid to intra-individual decline, which improves the identification of those individuals with prodromal AD. The proposed criteria emphasise the specificity of memory changes of AD and the need to use specific memory tests. It is noteworthy that most of the current memory tests do not record whether items to be recalled have been truly registered. Effective encoding of information should be controlled in order to exclude memory deficit related to anxiety, depression, frontal dysfunction or any other functional disorder. In the same way, identification of AD can be improved by using semantic cueing that facilitates the retrieval of stored information in aged healthy people or in patients with subcorticofrontal dysfunction.
Reduced benefit of cueing at recall reliably identifies prodromal AD. detecting AD-pathology-specific markers such as amyloid imaging, the weighting of the supportive features may change. We recognise that these criteria represent a cultural shift requiring more biologically focused work-up than previous approaches. However, this seems to be the best way to integrate the advances into the clinical arena. When effective disease-modifying medications are available, the argument for such biologically based studies will be even more compelling.
Validation studies are required because it is assumed that the proposed diagnostic criteria indicate the presence of the neurodegenerative process of AD. In addition, we recognise that the multidisciplinary approach required for our diagnostic framework
may not yet be feasible in all memory clinics, and certainly not in most epidemiological studies. However, these proposed criteria acknowledge the progress that has been made in the last two decades in refining our understanding of the neurobiology and clinical phenomenology of AD. Their usefulness will be determined in the future as investigators apply the criteria in a variety of research studies and as key issues in their application are resolved. ■ Volume loss of hippocampi, entorhinal cortex or amygdala evidenced on MRI with:
• qualitative ratings using visual scoring (referenced to well characterised population with age norms) or quantitative volumetry of regions of interest (referenced to well characterised population with age norms). C. Abnormal CSF biomarkers:
• decreased Aβ 1-42 and/or increased total tau and/or increased phospho-tau;
• other well validated markers to be discovered in the future. D. Specific pattern in functional neuroimaging with PET:
• reduced glucose metabolism in bilateral temporal parietal regions;
• other well validated ligands, including those that will emerge such as PiB or FDDNP. Exclusion Criteria History:
• sudden onset;
• early occurrence of the following symptoms -gait disturbances, seizures, behavioural changes. Clinical features:
• focal neurological features including hemiparesis, sensory loss, visual field deficits;
• early extrapyramidal signs. Other medical conditions severe enough to account for memory and related symptoms:
• non-AD dementia;
• major depression;
• cerebrovascular disease;
• toxic and metabolic abnormalities, all of which may require specific investigation;
• MRI FLAIR or T2 signal abnormalities in the MTL that are consistent with infectious or vascular insults. 
